Literature DB >> 2425961

Affective illness and S-adenosyl methionine: a preliminary report.

M W Carney, J Edeh, T Bottiglieri, E M Reynolds, B K Toone.   

Abstract

S-Adenosyl methionine may well have an antidepressant action beyond a placebo effect but this is virtually confined to endogenous depression. This should be subjected to further study. Our own double-blind placebo-controlled study is still incomplete. The indications are that SAM specifically affects folate, dopamine, and serotonin metabolism as well as activating and switching brain mechanisms. This suggests exciting prospects for further investigations. SAM is a nontoxic physiological metabolite virtually free of side effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425961     DOI: 10.1097/00002826-198608000-00005

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  9 in total

1.  Influence of S-adenosyl-L-methionine on chronic mild stress-induced anhedonia in castrated rats.

Authors:  A Benelli; M Filaferro; A Bertolini; S Genedani
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 2.  S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.

Authors:  Anup Sharma; Patricia Gerbarg; Teodoro Bottiglieri; Lila Massoumi; Linda L Carpenter; Helen Lavretsky; Philip R Muskin; Richard P Brown; David Mischoulon
Journal:  J Clin Psychiatry       Date:  2017-06       Impact factor: 4.384

Review 3.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

4.  Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine.

Authors:  T Bottiglieri; P Godfrey; T Flynn; M W Carney; B K Toone; E H Reynolds
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

Review 5.  Epigenetic therapeutics in autoimmune disease.

Authors:  Moshe Szyf
Journal:  Clin Rev Allergy Immunol       Date:  2010-08       Impact factor: 8.667

Review 6.  S-adenosyl-methionine in depression: a comprehensive review of the literature.

Authors:  George I Papakostas; Jonathan E Alpert; Maurizio Fava
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

Review 7.  S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism.

Authors:  H A Friedel; K L Goa; P Benfield
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 8.  S-adenosyl methionine (SAMe) for depression in adults.

Authors:  Ilaria Galizia; Lucio Oldani; Karine Macritchie; Erica Amari; Dominic Dougall; Tessa N Jones; Raymond W Lam; Guido Jacopo Massei; Lakshmi N Yatham; Allan H Young
Journal:  Cochrane Database Syst Rev       Date:  2016-10-10

Review 9.  S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review.

Authors:  Alessandro Cuomo; Bruno Beccarini Crescenzi; Simone Bolognesi; Arianna Goracci; Despoina Koukouna; Rodolfo Rossi; Andrea Fagiolini
Journal:  Ann Gen Psychiatry       Date:  2020-09-05       Impact factor: 3.455

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.